Dr. Scott Sigman, principal investigator and lead author, reported today positive results from the first-ever use of laser therapy to treat a COVID-19 pneumonia patient.
The innovative and patented Multiwave Locked System (MLS) Therapy Laser was developed in an effort to produce an efficient and simultaneous effect on pain, inflammation, and edema, exceeding the limits of traditional LLLT (low power) and concerns of HP (high power) laser therapy.
Find out what lies ahead in 2020 and beyond, and learn proven strategies to combat mounting uncertainties you may be facing including: opioid legislative changes, changing patient demographics, new barriers to treating patients with traditional methods, bottom line and top-line pressures, market consolidation, and more!
The Multiwave Locked System (MLS) emission precisely synchronizes simultaneous dual wavelengths, as well as simultaneous continuous and pulse emisions, resulting in optimum clinical effectiveness. The MLS emission provides more efficient biostimulatory results, with less energy, in considerably reduced times compared to traditional laser therapy.
Case of a 17 year old female who suffered from severe lumbalgia and radiculopathy into the left leg. The purpose of this clinical case was to ...